C11orf95 Inhibitors
C11orf95 inhibitors are an assorted group of compounds that downregulate or inhibit the activity of the C11orf95 protein by various mechanisms. Kinase inhibitors like staurosporine and Go6983 operate by blocking the kinase activity needed for the phosphorylation processes that C11orf95 may rely on for its functional role in signaling pathways. PI3K inhibitors such as LY294002 and wortmannin specifically target the PI3K/Akt signaling axis, a common pathway that influences numerous cellular functions and could be critical for C11orf95 activity. By inhibiting this pathway, these compounds can indirectly lead to decreased activity of C11orf95.
Further inhibitory actions come from compounds like rapamycin and U0126, which target mTOR and MEK1/2, respectively. Rapamycin binds to mTOR complex 1 (mTORC1) and inhibits its activity, which is crucial for cellular processes such as protein synthesis and autophagy. Since the mTOR pathway is a major regulator of cell growth and survival, its inhibition can have significant effects on the cellular functions that may involve C11orf95. U0126, on the other hand, specifically inhibits MEK1/2, which are upstream activators of the ERK pathway, a pathway that plays a vital role in cell proliferation, differentiation, and survival. If C11orf95 activity is contingent upon the MAPK/ERK signaling cascade, then the inhibition by U0126 would result in a decrease in C11orf95-mediated signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can inhibit multiple isoforms non-selectively. Its action on protein kinase C (PKC) leads to the disruption of downstream signaling cascades, potentially attenuating the phosphorylation events that C11orf95 may be involved in, thereby diminishing C11orf95's functional activity in signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By blocking PI3K activity, it prevents the activation of downstream signaling elements, such as Akt. As C11orf95 is implicated in signaling pathways, its activity can be indirectly inhibited as the PI3K/Akt pathway is suppressed, which could affect the cellular processes C11orf95 regulates. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which can suppress the mTOR signaling pathway involved in cell growth and proliferation. Inhibition of mTOR could negatively affect C11orf95 if its function is tied to pathways that are downstream or influenced by mTOR activity, leading to reduced activity of C11orf95 due to a decrease in cellular growth signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key components of the MAPK/ERK pathway. By inhibiting MEK, U0126 prevents the activation of ERK, which could be upstream of C11orf95. If C11orf95 is part of this signaling cascade, its functional activity could be indirectly inhibited due to the suppressed ERK activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which interferes with the p38 MAPK signaling pathway. Since the p38 MAPK pathway is involved in inflammatory responses and stress signals, if C11orf95 is modulated by these signals, SB203580's inhibition of p38 MAPK could lead to a decrease in C11orf95 activity. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of Gsα subunit of G-proteins. If C11orf95's activity is regulated by G-protein coupled receptor (GPCR) signaling, inhibition of Gsα by NF449 could diminish the functional activity of C11orf95 by reducing GPCR-mediated signaling events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK1, which is involved in the MAPK/ERK pathway. By preventing MEK1 from activating ERK, PD98059 indirectly reduces the activity of downstream proteins that are regulated by the ERK pathway, which could include C11orf95. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. Inhibition of JNK by SP600125 can lead to reduced transcriptional activity of AP-1, which could affect C11orf95 if its activity is modulated by AP-1 regulated genes. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase). By inhibiting V-ATPase, it disrupts endosomal acidification and autophagic processes, which could indirectly inhibit C11orf95 if its functional activity relies on endosomal signaling or autophagy-related pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a pan-PKC inhibitor with a broad range of action within PKC isoforms. By inhibiting PKC, it can attenuate signaling pathways that involve PKC-mediated phosphorylation events, potentially reducing C11orf95 activity if it is regulated by such phosphorylation processes. | ||||||